HCPCS Level II code J1436 designates the injection of etidronate disodium, billed per 300 mg unit. This code is nationally relevant for payers and providers involved in administering parenteral bisphosphonate therapy in outpatient and ambulatory infusion settings. Accurate coding ensures proper identification of the drug product and supports claims processing and utilization tracking across commercial and public payers.

Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for etidronate injections, common sites of service, and the role of J1436 in medical billing. The publication outlines benchmarks and reimbursement considerations, payer coverage patterns, and recent policy notes affecting injectable drug coding where available. Clinical implications, coding nuances, and administrative considerations for claims submission are summarized to inform billing teams, pharmacists, and clinicians. Data not available in the input is noted where applicable.